New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Lower Risk of Death and Kidney Failure Associated with Higher Target (vs. Below-Target) Doses of RAS Inhibitors in Octogenarians with HFrEF.
Lower Risk of Death and Kidney Failure Associated with Higher Target (vs. Below-Target) Doses of RAS Inhibitors in Octogenarians with HFrEF. The American journal of medicine Sin, M. K., Allman, R. M., Faselis, C., Aronow, W. S., Brown, C. J., Lam, P. H., Wu, W. C., Zeng-Treitler, Q., Patel, S. S., Raman, V. K., Zhang, S., Sheriff, H. M., Morgan, C. J., Heidenreich, P. A., Fonarow, G. C., Ahmed, A. 2024Abstract
Renin-angiotensin system inhibitors (RASIs) at higher target doses reduce the risk of death in patients with heart failure with reduced ejection fraction (HFrEF). Less is known about their effectiveness in octogenarians, the examination of which was the objective of this study.Of 32,964 Veterans =80 years with HFrEF (ejection fraction =40%) receiving RASIs, 6655 received target-dose. Using propensity scores for target-dose, calculated for each of 32,964 patients, we assembled a matched cohort of 13,284 patients balanced on 66 baseline characteristics. Hazard ratios (95% CI) for 5-year mortality and kidney failure associated with target (vs. below-target) dose RASI were estimated in the matched cohort. Kidney failure was defined as receipt of kidney replacement therapy or estimated glomerular filtration rate (eGFR) <15 mL/min/1.73m2 measured twice >30 days apart.Patients had mean(±SD) age 84.5(±3.4) years, EF 31.3(±8.2) %, and eGFR 58.5(±18.2) mL/min/1.73m2. All-cause mortality occurred in 71.2% and 69.5% of matched patients in below-target and target dose RASI groups, respectively (HR associated with target-dose RASI, 0.95; 95% CI, 0.91-0.99; p=0.009). Respective rates for kidney failure were 1.8% and 1.5%, with a trend toward a lower risk in the target-dose group (HR, 0.80; 95% CI, 0.61-1.04; p=0.094). Consequently, there was a lower risk of the composite endpoint of kidney failure or death (HR, 0.94; 95% CI, 0.91-0.98; p=0.004).These findings provide evidence that in octogenarians with HFrEF, the use of RASIs in higher target (vs. below-target) doses was associated with lower risks of death and kidney failure.
View details for DOI 10.1016/j.amjmed.2024.10.019
View details for PubMedID 39551174